August 5, 2024
“Stocks fell sharply on Friday as a much weaker-than-anticipated jobs report for July ignited worries that the economy could be falling into a recession. The broad market index dropped 1.84% to end at 5,346.56. The Nasdaq Composite lost 2.43% to close at 16,776.16, bringing… Continue Reading…
August 2, 2024
“…So what gives? Should investors be worried? In short, probably not. Stocks naturally retreat after big gains. It’s to be expected; in fact, it’s healthy. Yes, 18% is a lot, many stocks move less over the course of a year,… Continue Reading…
August 1, 2024
“Shares of global semiconductor firms rallied on Wednesday as they were boosted by some positive earnings in the sector and a report of potentially less severe U.S. export restrictions on China. AMD was among the big winners with shares up… Continue Reading…
August 1, 2024
“Twelve stocks in the S&P 500, including Walgreens Boots Alliance (WBA), Dexcom (DXCM) and Super Micro Computer (SMCI), have already crashed 40% or more from their 52-week highs, says an Investor’s Business Daily analysis of data from S&P Global Market Intelligence and MarketSurge. A 40% decline is… Continue Reading…
July 31, 2024
“…RegenXBio (RGNX) The first Goldman pick we’ll look at is RegenXBio, a gene therapy company specializing in single-dose treatments for severe diseases with few or no existing therapies…. Choi rates RGNX a Buy along with a $38 price target. This… Continue Reading…
July 31, 2024
“…The private equity firm sold 41.6 million Nasdaq shares for $65.30 each, according to a statement by the exchange operator Monday. A Thoma Bravo affiliate was offering the stock for between $64.80 and $65.80 each, Bloomberg News reported Friday. The… Continue Reading…
July 30, 2024
“Here’s what the company reported compared with what Wall Street was expecting, based on a survey of analysts by LSEG: The fast-food giant reported second-quarter net income of $2.02 billion, or $2.80 per share, down from $2.31 billion, or $3.15… Continue Reading…
July 30, 2024
“Shares of Dexcom tumbled almost 40% in extended trading Thursday after the diabetes management company reported disappointing revenue for the second quarter and offered weak guidance. Here’s how the company did: Dexcom’s revenue increased 15% from $871.3 million a year earlier, according to a… Continue Reading…
Recent Comments